Answers are grounded in this paper and cite their sources.
¹⁸F-rhPSMA-7.3 offers a clinically meaningful verified detection rate for localization of recurrent prostate cancer. Despite missing the coprimary end point of combined region-level positive predictive value, the totality of the data support the potential clinical utility of ¹⁸F-rhPSMA-7.3.
No takes yet. Share an insight, caveat, or question.
Jani et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: